A phase II study of capecitabine plus cisplatin in metastatic triple-negative breast cancer patients pretreated with anthracyclines and taxanes

Phase III Open-Label Randomized Study of Eribulin Mesylate Versus Capecitabine in Patients With Locally Advanced or Metastatic Breast Cancer Previously Treated With an Anthracycline and a Taxane

(2015) Peter A. Kaufman et al.   JOURNAL OF CLINICAL ONCOLOGY

Cisplatin plus gemcitabine versus paclitaxel plus gemcitabine as first-line therapy for metastatic triple-negative breast cancer (CBCSG006): a randomised, open-label, multicentre, phase 3 trial

(2015) Xi-Chun Hu et al.   LANCET ONCOLOGY

Cisplatin and gemcitabine as the first line therapy in metastatic triple negative breast cancer

(2014) Jian Zhang et al.   INTERNATIONAL JOURNAL OF CANCER

Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial

(2014) Gunter von Minckwitz et al.   LANCET ONCOLOGY

Docetaxel–cisplatin might be superior to docetaxel–capecitabine in the first-line treatment of metastatic triple-negative breast cancer†

(2012) Y. Fan et al.   ANNALS OF ONCOLOGY

Capecitabine Versus Classical Cyclophosphamide, Methotrexate, and Fluorouracil As First-Line Chemotherapy for Advanced Breast Cancer

(2011) Martin R. Stockler et al.   JOURNAL OF CLINICAL ONCOLOGY

Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study

(2011) Javier Cortes et al.   LANCET

A phase II study of combination chemotherapy with capecitabine and cisplatin in patients with metastatic or recurrent squamous cell carcinoma of the head and neck

(2010) Y.- W. Won et al.   ANNALS OF ONCOLOGY

Efficacy of Neoadjuvant Cisplatin in Triple-Negative Breast Cancer

(2010) Daniel P. Silver et al.   JOURNAL OF CLINICAL ONCOLOGY

Survival Outcomes for Patients with Metastatic Triple-Negative Breast Cancer: Implications for Clinical Practice and Trial Design

(2009) Farrah Kassam et al.   Clinical Breast Cancer

Platinum-based chemotherapy in triple-negative breast cancer

(2008) B. Sirohi et al.   ANNALS OF ONCOLOGY

Capecitabine and Cisplatin Combination Is an Active and Well-Tolerated Doublet in the Treatment of Metastatic Breast Carcinoma Patients Pretreated with Anthracycline and Taxanes

(2008) Berna Öksüzoglu et al.   CHEMOTHERAPY

Triple-Negative Breast Cancer: Risk Factors to Potential Targets

(2008) B. P. Schneider et al.   CLINICAL CANCER RESEARCH

Basal-Like Breast Cancer: A Critical Review

(2008) Emad A. Rakha et al.   JOURNAL OF CLINICAL ONCOLOGY